Company intelligence / Profile preview
Mayfield Pharmaceuticals
USA
- Ownership
- Private
- Development stage
- Other
01
Overview
Mayfield Pharmaceuticals is focused on developing branded small molecule therapeutics targeting major unmet needs in women’s health, with its most advanced assets in preclinical or pre-IND planning. Lead programs address bacterial vaginosis (MAY-66; first-in-class), dyspareunia (MAY-44; topical non-estrogen), and moderate to severe interstitial cystitis (MAY-88; patent-pending oral suspension). Early data are reported as promising; clinical trials have not yet commenced as of latest public update.
- Therapeutic areas
- NephrologyWomen's Health
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Harrow Health
Beyond the preview
Go deeper on Mayfield Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mayfield Pharmaceuticals.